oncology
Lung

KRAS-targeted therapy shows promising first results in NSCLC


Until now KRAS-positive lung cancers have been considered ‘undruggable’ but early results with the first targeted therapy have shown promising and durable response rates. Presented at the World Congress on Lung Cancer 2019 meeting in Barcelona, the phase 1 study results...

Until now KRAS-positive lung cancers have been considered ‘undruggable’ but early results with the first targeted therapy have shown promising...

Read more